On-Demand Webinar · 40 min
Navigating Orphan Drug Regulations in the US and EU
The EU has revised its orphan drug framework – eligibility, exclusivity and incentive rules are diverging from the US. Our experts guide you how to build a coherent transatlantic strategy.
Designation criteria · US vs EU I Exclusivity mechanisms I EU market entry risks I Portfolio implications
Watch the webinar on-demand
Register in 30 seconds to unlock the full 40-minute session with AzurBio’s regulatory team.
Meet the speakers
3 regulatory experts from AzurBio walking you through the practicalities of orphan drug strategy in the US and EU.
Nadia Boehringer
COO Europe
MSc · MRA · Global Executive MBA
Sophie Lamaison
Associate Director, Regulatory Affairs
Pharm D · MRA
Samantha Gastine
Junior Consultant, Regulatory Affairs
Pharmacist Student